Avacta Group Plc (AVCTF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Avacta Group Plc (AVCTF) with AI Score 47/100 (Weak). Avacta Group Plc is a clinical-stage biopharmaceutical company focused on developing cancer therapies and diagnostics. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Avacta Group Plc (AVCTF) Healthcare & Pipeline Overview
Avacta Group Plc is a clinical-stage biopharmaceutical company developing cancer therapies and diagnostics using its proprietary Affimer and pre|CISION platforms. With operations in the UK, North America, and Asia, Avacta focuses on novel immunotherapies and diagnostic assays, differentiating itself through research collaborations and strategic partnerships.
Investment Thesis
Avacta Group Plc presents a compelling, albeit high-risk, investment opportunity within the biotechnology sector. The company's proprietary Affimer and pre|CISION platforms offer potential for developing novel cancer therapies and diagnostics. Key value drivers include the advancement of its therapeutic pipeline through clinical trials and the expansion of its diagnostic product offerings. The partnerships with LG Chem, POINT Biopharma, and AffyXell represent significant growth catalysts. However, the company's negative profit margin of -30398.2% and gross margin of -1217.9% highlight the financial risks associated with investing in a clinical-stage biopharmaceutical company. Successful clinical trial outcomes and regulatory approvals are critical for realizing the company's long-term potential. Investors should closely monitor the progress of Avacta's clinical programs and its ability to secure additional funding to support its research and development activities.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.42 billion indicates a relatively small but potentially high-growth company.
- Negative P/E ratio of -15.90 reflects the company's current lack of profitability, typical for clinical-stage biopharmaceutical companies.
- Profit margin of -30398.2% highlights the significant expenses associated with research and development in the biotechnology industry.
- Gross margin of -1217.9% indicates that the cost of goods sold exceeds revenue, requiring substantial external funding.
- Beta of -0.24 suggests that the stock price is less volatile than the overall market.
Competitors & Peers
Strengths
- Proprietary Affimer and pre|CISION platforms.
- Strategic partnerships with leading pharmaceutical companies.
- Clinical-stage pipeline of novel cancer therapies.
- Experienced management team.
Weaknesses
- Negative profit margin and gross margin.
- High research and development costs.
- Reliance on external funding.
- Limited commercialized products.
Catalysts
- Upcoming: Clinical trial results for lead therapeutic candidates expected in the next 12-18 months.
- Ongoing: Expansion of strategic partnerships and licensing agreements.
- Ongoing: Development of novel diagnostic assays based on the Affimer platform.
- Ongoing: Application of pre|CISION technology to new chemotherapy drugs.
Risks
- Potential: Clinical trial failures could negatively impact the company's stock price.
- Potential: Regulatory hurdles and lengthy approval processes could delay the commercialization of its products.
- Ongoing: Competition from other biotechnology companies could erode market share.
- Ongoing: Economic downturn and reduced funding for research and development could limit the company's growth.
Growth Opportunities
- Expansion of Therapeutic Pipeline: Avacta has the opportunity to expand its therapeutic pipeline by advancing its current programs through clinical trials and developing new therapies based on its Affimer and pre|CISION platforms. The market for cancer therapies is projected to reach $200 billion by 2028, offering significant revenue potential. Successful clinical trial outcomes and regulatory approvals are critical milestones for realizing this opportunity. Timeline: Ongoing, with clinical trial results expected in the next 12-24 months.
- Strategic Partnerships and Licensing Agreements: Avacta can leverage strategic partnerships and licensing agreements to accelerate the development and commercialization of its technologies. The partnership with POINT Biopharma for tumor-activated radiopharmaceuticals demonstrates this approach. Expanding these collaborations can provide access to new markets, technologies, and funding. Timeline: Ongoing, with potential for new partnerships in the next 6-12 months.
- Development of Novel Diagnostic Assays: Avacta's Affimer platform can be used to develop novel diagnostic assays for a wide range of diseases. The company's AffiDX SARS-CoV-2 lateral flow rapid antigen test demonstrates the potential of this platform. Expanding the diagnostic product line can generate revenue and establish Avacta as a leader in the diagnostics market. Timeline: Ongoing, with potential for new product launches in the next 12-18 months.
- Application of pre|CISION Technology: The pre|CISION platform offers the potential to selectively activate chemotherapy drugs in the tumor microenvironment, reducing systemic toxicity. This technology can be applied to a wide range of chemotherapy drugs, offering a significant advantage over traditional chemotherapy. Further development and validation of this technology can lead to new and improved cancer therapies. Timeline: Ongoing, with preclinical and clinical studies planned for the next 12-24 months.
- Expansion into New Geographic Markets: Avacta can expand its geographic reach by entering new markets in Asia and Europe. The company already has operations in the United Kingdom, North America, and South Korea. Expanding into new markets can increase revenue and diversify the company's geographic risk. Timeline: Ongoing, with potential for expansion into new markets in the next 24-36 months.
Opportunities
- Expansion of therapeutic pipeline through clinical trials.
- Development of novel diagnostic assays.
- Application of pre|CISION technology to new chemotherapy drugs.
- Expansion into new geographic markets.
Threats
- Competition from other biotechnology companies.
- Regulatory hurdles and lengthy approval processes.
- Clinical trial failures.
- Economic downturn and reduced funding for research and development.
Competitive Advantages
- Proprietary Affimer and pre|CISION platforms provide a technological advantage.
- Strategic partnerships with leading pharmaceutical and diagnostic companies.
- Strong intellectual property portfolio protects its technologies.
- Clinical-stage pipeline of novel cancer therapies.
About AVCTF
Avacta Group Plc, established in 2003 and based in Wetherby, United Kingdom, is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies and diagnostics. The company's core technologies are its proprietary Affimer and pre|CISION platforms. The Affimer platform is used to develop custom Affimer proteins for customer products and in-house diagnostic assays, including the AffiDX SARS-CoV-2 lateral flow rapid antigen tests. The pre|CISION platform is designed to selectively activate chemotherapy drugs in the tumor microenvironment, reducing systemic toxicity. Avacta operates through two segments: Diagnostics and Therapeutics. Its therapeutic pipeline focuses on novel cancer immunotherapies, combining its proprietary platforms to target and treat tumors more effectively. The company has established several strategic collaborations, including a research collaboration with pre|CISION technology incorporating a substrate sensitive to fibroblast activation protein alpha, a drug development collaboration with LG Chem Life Sciences, a partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies, a licensing agreement with POINT Biopharma Inc. for the development of tumor-activated radiopharmaceuticals, and a drug development partnership with AffyXell to develop engineered mesenchymal stem cells for autoimmune diseases. Avacta's geographic reach extends across the United Kingdom, North America, South Korea, and the rest of Asia and Europe.
What They Do
- Develops cancer therapies based on its Affimer and pre|CISION platforms.
- Creates diagnostic assays for various diseases.
- Develops custom Affimer proteins for customer products.
- Offers AffiDX SARS-CoV-2 lateral flow rapid antigen tests.
- Creates novel cancer immunotherapies.
- Partners with other companies for drug development and research.
Business Model
- Develops and commercializes cancer therapies and diagnostic assays.
- Generates revenue through product sales and licensing agreements.
- Collaborates with other companies for research and development.
- Out-licenses its Affimer and pre|CISION platforms to third parties.
Industry Context
Avacta Group Plc operates in the biotechnology industry, a sector characterized by intense competition, high research and development costs, and lengthy regulatory approval processes. The market for cancer therapies and diagnostics is substantial and growing, driven by an aging population and increasing incidence of cancer. Key trends in the industry include the development of personalized medicine, immunotherapies, and targeted drug delivery systems. Avacta's Affimer and pre|CISION platforms position it to capitalize on these trends. Competitors include companies such as BOVNF, CLVLY, CMVLF, CRLBF, and HLOSF, each pursuing different approaches to cancer treatment and diagnostics.
Key Customers
- Pharmaceutical companies seeking novel drug targets and therapies.
- Diagnostic companies looking for innovative diagnostic assays.
- Research institutions conducting research on cancer and other diseases.
- Patients in need of effective cancer therapies and diagnostic tests.
Financials
Chart & Info
Avacta Group Plc (AVCTF) stock price: Price data unavailable
Latest News
-
With 75% institutional ownership, Avacta Group Plc (LON:AVCT) is a favorite amongst the big guns
Simply Wall St. · Feb 15, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AVCTF.
Price Targets
Wall Street price target analysis for AVCTF.
MoonshotScore
What does this score mean?
The MoonshotScore rates AVCTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christina Marie Coughlin
CEO
Christina Marie Coughlin serves as the CEO of Avacta Group Plc. Her background includes extensive experience in the biopharmaceutical industry, with a focus on oncology and drug development. She has held leadership positions at various pharmaceutical companies, contributing to the development and commercialization of several successful therapies. Her expertise spans clinical development, regulatory affairs, and commercial strategy. She brings a wealth of knowledge and a proven track record to Avacta.
Track Record: Since assuming the role of CEO, Christina Marie Coughlin has focused on advancing Avacta's clinical programs and expanding its strategic partnerships. Key milestones under her leadership include the progression of the therapeutic pipeline through clinical trials and the establishment of collaborations with LG Chem, POINT Biopharma, and AffyXell. She has also overseen the development of novel diagnostic assays and the expansion of the company's geographic reach.
AVCTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Avacta Group Plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited liquidity and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in AVCTF.
- Lower liquidity compared to major exchanges can lead to price volatility.
- OTC Other tier stocks may be subject to less regulatory oversight.
- The company's ability to meet future financial obligations is uncertain.
- Potential for delisting or suspension from the OTC market.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property portfolio.
- Review the company's clinical trial results and regulatory approvals.
- Monitor the company's cash flow and financial stability.
- Consult with a financial advisor before investing.
- The company's proprietary Affimer and pre|CISION platforms.
- Strategic partnerships with leading pharmaceutical companies.
- Clinical-stage pipeline of novel cancer therapies.
- Experienced management team.
Common Questions About AVCTF
What does Avacta Group Plc do?
Avacta Group Plc is a clinical-stage biopharmaceutical company focused on developing cancer therapies and diagnostics. The company leverages its proprietary Affimer and pre|CISION platforms to create novel immunotherapies and diagnostic assays. Its therapeutic pipeline focuses on selectively activating chemotherapy drugs in the tumor microenvironment, reducing systemic toxicity. Avacta also develops diagnostic assays, including the AffiDX SARS-CoV-2 lateral flow rapid antigen tests. The company operates through Diagnostics and Therapeutics segments, collaborating with pharmaceutical and diagnostic companies to advance its technologies.
What do analysts say about AVCTF stock?
Analyst coverage for AVCTF is limited due to its OTC listing and smaller market capitalization. However, analysts generally view the company's proprietary Affimer and pre|CISION platforms as promising technologies with the potential to generate significant value. Key valuation metrics include the company's pipeline of clinical-stage assets and its partnerships with leading pharmaceutical companies. Growth considerations include the successful completion of clinical trials and the commercialization of its products. Investors should conduct their own due diligence and consider the risks associated with investing in a clinical-stage biopharmaceutical company.
What are the main risks for AVCTF?
The main risks for AVCTF include clinical trial failures, regulatory hurdles, competition from other biotechnology companies, and reliance on external funding. Clinical trial failures could negatively impact the company's stock price and delay the commercialization of its products. Regulatory hurdles and lengthy approval processes could also delay the commercialization of its products. Competition from other biotechnology companies could erode market share. The company's reliance on external funding makes it vulnerable to economic downturns and reduced funding for research and development.
What are the key factors to evaluate for AVCTF?
Avacta Group Plc (AVCTF) currently holds an AI score of 47/100, indicating low score. Key strength: Proprietary Affimer and pre|CISION platforms.. Primary risk to monitor: Potential: Clinical trial failures could negatively impact the company's stock price.. This is not financial advice.
How frequently does AVCTF data refresh on this page?
AVCTF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AVCTF's recent stock price performance?
Recent price movement in Avacta Group Plc (AVCTF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary Affimer and pre|CISION platforms.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AVCTF overvalued or undervalued right now?
Determining whether Avacta Group Plc (AVCTF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AVCTF?
Before investing in Avacta Group Plc (AVCTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC stocks carry additional risks due to limited disclosure and liquidity.